Myriad Accelerates MRD Assay Launch, Data Bolsters Clinical Utility
Event summary
- Myriad Genetics plans to launch its Precise MRD assay in March 2026, initially targeting breast cancer clinicians, followed by colorectal and renal cancers later in 2026.
- Interim study data (MONITOR-Breast and MONSTAR-SCREEN-3) demonstrate high baseline sensitivity (93% in breast cancer, 100% in colorectal cancer) and predictive capabilities for recurrence and treatment response.
- Precise MRD utilizes whole-genome sequencing to detect ctDNA down to one part per million (ppm), a significant improvement over first-generation assays.
- The company has presented its MRD strategy at industry forums including ASCO Gastrointestinal Cancers Symposium and the J.P. Morgan Healthcare Conference.
- MONSTAR-SCREEN-3 showed a one-month post-surgery recurrence prediction sensitivity of 100%.
The big picture
Myriad's accelerated launch of Precise MRD aligns with the growing trend towards personalized oncology and the increasing adoption of liquid biopsies for cancer monitoring. The assay's ability to detect ctDNA at extremely low levels positions Myriad to capitalize on the demand for more precise and earlier cancer detection, but success hinges on demonstrating clinical utility and securing reimbursement. The company's reliance on observational studies for validation also introduces a degree of uncertainty regarding real-world effectiveness.
What we're watching
- Adoption Rate
- The initial uptake by community-based clinicians in March 2026 will be a key indicator of Precise MRD’s commercial viability and Myriad’s ability to penetrate the market.
- Clinical Validation
- Continued validation of Precise MRD’s predictive power across a broader range of cancer types and patient populations will be crucial for expanding its clinical utility and reimbursement coverage.
- Competitive Landscape
- The emergence of competing ultrasensitive MRD assays and the potential for consolidation within the molecular diagnostics space could impact Myriad’s market share and pricing power.
Related topics